Health Technology Alim

Alimera Sciences, Inc.

ALIM | $3.6 0.28% 0.28% 7.7K

(0.0% 1d) (-10.0% 1m) (70.5% 1y) (0.0% 2d) (1.4% 3d) (7.5% 7d) (-37.69% volume)
Earnings Calendar: 2023-10-26
Market Cap: $ 188,476,020
http://www.alimerasciences.com
Sec Filling | Patents | 127 employees

(US) Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

diabetes diabetic macular treatment

Drugs

Iluvien (fluocinolone acetonide)

add to watch list Paper trade email alert is off

Press-releases

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -11.36% | O: 0.0% H: 0.0% C: -3.95%
nasdaq sciences grants

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -10.25% | O: 0.0% H: 2.25% C: 1.25%
first retina network trial

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -7.24% | O: -1.55% H: 8.14% C: 2.36%
year sciences results

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| 7.49% | O: 1.8% H: 6.47% C: 4.12%
report year update sciences financial

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -9.8% | O: -0.75% H: 3.04% C: -1.52%
iluvien institute macular health natural care diabetic

Alimera Completes Recruitment for the Synchronicity Study
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -7.95% | O: 0.0% H: 3.33% C: 2.44%
study

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 13:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -16.9% | O: 1.39% H: 0.0% C: -6.85%
nasdaq sciences grant financial

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-12 (Crawled : 12:30) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| -3.23% | O: 1.35% H: 6.25% C: -0.27%
nasdaq sciences grant

Alimera Appoints Maggie A. Pax to Its Board of Directors
Published: 2023-11-08 (Crawled : 22:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| 5.59% | O: -1.68% H: 4.64% C: 2.31%

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
ALIM | $3.6 0.28% 0.28% 7.7K

Health Technology

| 9.12% | O: 2.74% H: 0.0% C: -0.89%
iluvien

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001104659-24-042348	4	2024-04-02	2024-03-26	Sell	F	12103	118274
0001104659-24-034104	4	2024-03-14	2024-03-11	Buy	A	1800	1800
0001104659-24-034103	4	2024-03-14	2024-03-11	Buy	A	125000	125000
0001104659-24-034103	4	2024-03-14	2024-03-11	Buy	A	125000	125000
0001104659-24-034101	4	2024-03-14	2024-03-11	Buy	A	14700	14700
0001104659-24-034100	4	2024-03-14	2024-03-11	Buy	A	75000	75000
0001104659-24-034100	4	2024-03-14	2024-03-11	Buy	A	6800	6800